SEC Filing Summary: Rexahn Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on September 28, 2015. The filing serves as a Regulation FD disclosure regarding the presentation of preliminary clinical data at the 18th ECCO-40th ESMO European Cancer Congress 2015. The data pertains to the Company's anti-cancer compounds, Supinoxin™ and RX-3117, which are in ongoing Phase I studies.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary event is the dissemination of scientific data via poster presentations.
Outlook, Risks, and Management Commentary
- Management Commentary: The Company announced the presentation of preliminary clinical data for Supinoxin™ and RX-3117.
- Exhibits: A press release detailing the clinical data is included as Exhibit 99.1.
- Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent nature of ongoing Phase I clinical studies.
Key Facts for Investor Verification
- Verify the specific preliminary clinical data results for Supinoxin™ and RX-3117 in the attached press release (Exhibit 99.1).
- Confirm the current status and timeline of the Phase I studies mentioned.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial health.
- Ensure the company name is correctly identified as Rexahn Pharmaceuticals, Inc., despite the metadata reference to Opus Genetics, Inc.